15 Aug Direct oral anticoagulants and the risk of major bleeding in patients with non-valvular atrial fibrillation (Q17-01)
Direct oral anticoagulants and the risk of major bleeding in patients with non-valvular atrial fibrillation (Q17-01)
What is the issue?
- Vitamin K antagonists (warfarin) have been the first line of anticoagulation therapy for AF for years; however, direct oral anticoagulants (DOACs) are progressively replacing warfarin. Information on the real world safety and effectiveness of DOACs is needed.
- This project is an international collaboration with the European Medicines Agency (EMA).
What was the aim of the study?
- To establish the risk of major bleeding in direct oral anticoagulant (DOAC) users versus vitamin K antagonist (VKA) users, using health care databases from four European countries and six provinces in Canada.
Van den Ham HA, Souverein PC, Klungel OH, Platt RW, Ernst P, Dell’Aniello S, Schmiedl S, Rottenkolber M, Huerta C, Martín Merino E, León-Muñoz LM, Montero D, Andersen M, Aakjær M, De Bruin M, Gardarsdottir H. Major bleeding in users of direct oral anticoagulants in atrial fibrillation: a pooled analysis of results from multiple population-based cohort studies. Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1339-1352.